Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2026)
Design Therapeutics recorded quarterly Cash from Financing Activities of $19.9 million in Q1 2026, down 21.26% quarter-over-quarter from $25.3 million in Q4 2025, and up 86569.57% year-over-year from N/an in Q1 2025.
Design Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $19.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 86569.57% year-over-year to $19.9 million; the TTM figure through Mar 2026 stood at $45.6 million (up 8746.71% YoY), while the FY2025 annual figure was $25.7 million, up 4917.15% from the prior year.
- Cash from Financing Activities came in at $19.9 million for Q1 2026 at Design Therapeutics, down from $25.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $25.3 million in Q4 2025 to a low of -$202000.0 in Q2 2022.
- A 5-year average of $3.1 million and a median of $151000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities tumbled 4140.0% in 2022 and soared 86569.57% in 2026, its largest moves.
- Design Therapeutics' Cash from Financing Activities stood at $130000.0 in 2022, then surged by 285.38% to $501000.0 in 2023, then sank by 47.5% to $263000.0 in 2024, then surged by 9526.24% to $25.3 million in 2025, then dropped by 21.26% to $19.9 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $19.9 million, $25.3 million, and $37000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 19.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.93 Mn |
| Mar 31, 2026 | 19.93 Mn |
| Dec 31, 2025 | 25.32 Mn |
| Dec 31, 2025 | 25.32 Mn |
| Sep 30, 2025 | 37,000.00 |
| Sep 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 361,000.00 |
| Jun 30, 2025 | 361,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 501,000.00 |
| Dec 31, 2023 | 501,000.00 |
| Sep 30, 2023 | 13,000.00 |
| Sep 30, 2023 | 13,000.00 |
| Dec 31, 2022 | 130,000.00 |
| Dec 31, 2022 | 130,000.00 |
| Sep 30, 2022 | 151,000.00 |
| Sep 30, 2022 | 151,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Mar 31, 2022 | 156,000.00 |
| Mar 31, 2022 | 156,000.00 |
| Dec 31, 2021 | 193,000.00 |
| Dec 31, 2021 | 193,000.00 |
| Sep 30, 2021 | 30,000.00 |
| Sep 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 5,000.00 |
| Jun 30, 2021 | 5,000.00 |
| Mar 31, 2021 | 378.98 Mn |
| Mar 31, 2021 | 378.98 Mn |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Mar 31, 2020 | 44.53 Mn |
| Mar 31, 2020 | 44.53 Mn |